Sun Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries is currently trading at Rs. 576.35, up by 6.40 points or 1.12% from its previous closing of Rs. 569.95 on the BSE.

The scrip opened at Rs. 578.00 and has touched a high and low of Rs. 580.00 and Rs. 576.00 respectively. So far 7328 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 610.00 on 02-May-2012 and a 52 week low of Rs. 436.50 on 26-May-2011.

Last one week high and low of the scrip stood at Rs. 596.85 and Rs. 560.30 respectively. The current market cap of the company is Rs. 59022.99 crore.

The promoters holding in the company stood at 63.72 % while Institutions and Non-Institutions held 25.49 % and 10.80 % respectively.

Sun Pharmaceutical Industries’ subsidiary has been granted USFDA an approval for its Abbreviated New Drug Application (ANDA) for its generic version of Astelin, Azelastine HCL Nasal Spray, 0.1% (137 mcg/spray). This generic Azelastine HCL Nasal Spray, 0.1% (137 mcg/spray) is therapeutically equivalent to Astelin Nasal Spray from Medpointe Pharm HLC. Azelastine HCL nasal spray has annual sales of approximately $ 144 million in the US.

Azelastine HCL Nasal Spray is indicated for the treatment of the symptoms of seasonal allergic rhinitis such asrhinorrhea, sneezing and nasal pruritus; and the symptoms of vasomotor rhinitis, such as rhinorrhea, nasal congestion and postnasal drip in adults and children 12 years and older.

Sun Pharmaceutical Industries is an international, integrated, speciality pharmaceutical company. It manufactures and markets a large basket of pharmaceutical formulations as branded generics as well as generics in India, US and several other markets across the world.